Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
September 28, 2020 08:55 ET
|
Sarepta Therapeutics, Inc.
--Results demonstrate continued safety and tolerability of SRP-9001 in four participants with Duchenne -- --All four participants demonstrated improvements in NSAA scores compared to baseline...
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
September 15, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 21 recipients of Route 79,...
Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
September 14, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time -- -- Additional poster presentations at WMS will highlight data from Sarepta’s RNA and gene therapy programs...
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
September 09, 2020 17:19 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has completed a...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2020...
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
August 25, 2020 08:45 ET
|
Sarepta Therapeutics, Inc.
-- FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 ---- FDA has indicated it does not currently plan to hold an advisory committee meeting to discuss the...
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
August 11, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.; University of Florida
CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and the University of...
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 05, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
– Net product sales of $111.3 million, an 18% increase over same quarter of prior year – CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2020 that...